Molecular modeling and in vitro studies of a neutral oxime as a potential reactivator for acetylcholinesterase inhibited by paraoxon

Article abstract of DOI:10.3390/molecules23112954

The present work aimed to compare the small, neutral and monoaromatic oxime, isatin-3-oxime (isatin-O), to the commercial ones, pralidoxime (2-PAM) and obidoxime, in a search for a new potential reactivator for acetylcholinesterase (AChE) inhibited by the pesticide paraoxon (AChE/POX) as well as a novel potential scaffold for further synthetic modifications. The multicriteria decision methods (MCDM) allowed the identification of the best docking poses of those molecules inside AChE/POX for further molecular dynamic (MD) studies, while Ellman’s modified method enabled in vitro inhibition and reactivation assays. In corroboration with the theoretical studies, our experimental results showed that isatin-O have a reactivation potential capable of overcoming 2-PAM at the initial moments of the assay. Despite not achieving better results than obidoxime, this molecule is promising for being an active neutral oxime with capacity of crossing the blood–brain barrier (BBB), to reactivate AChE/POX inside the central and peripheral nervous systems. Moreover, the fact that isatin-O can also act as anticonvulsant makes this molecule a possible multipotent reactivator. Besides, the MCDM method showed to be an accurate method for the selection of the best docking poses generated in the docking studies.

Full text of DOI:10.3390/molecules23112954

molecules
Article
Molecular Modeling and In Vitro Studies of a Neutral
Oxime as a Potential Reactivator for
Acetylcholinesterase Inhibited by Paraoxon
Reuel L. de Paula 1,2 , Joyce S. F. D. de Almeida 3 , Samir F. A. Cavalcante 2,4,
5
4
3,6
, Martin Valis 7,
Arlan S. Gonçalves
, Alessandro B. C. Simas , Tanos C. C. Franca
8
,
8
1,
Kamil Kuca * , Eugenie Nepovimova and José M. Granjeiro *
1
National Institute of Metrology, Quality and Technology (INMETRO), Avenida Nossa Senhora
das Graças 50, Duque de Caxias 25250-020, Brazil; reuel.lp@gmail.com
Brazilian Army CBRN Defense Institute (IDQBRN), Avenida das Américas 28705,
Rio de Janeiro 23020-470, Brazil; samir.cavalcante@eb.mil.br
Laboratory of Molecular Modeling Applied to Chemical and Biological Defense,
Military Institute of Engineering, Praça General Tibúrcio 80, Rio de Janeiro 22290-270, Brazil;
joycesfdalmeida@gmail.com (J.S.F.D.d.A.); tanosfranca@gmail.com (T.C.C.F.)
2
3
4
5
6
7
8
Walter Mors Institute of Research on Natural Products, Federal University of Rio de Janeiro (UFRJ),
CCS Bloco H Cidade Universitária, Rio de Janeiro 21941-902, Brazil; abcsimas@nppn.ufrj.br
Federal Institute of Education, Science and Technology, Avenida Ministro Salgado Filho S/N,
Vila Velha 29106-010, Brazil; arlansgoncalves@gmail.com
Center for Basic and Applied Research, Faculty of Informatics and Management,
University of Hradec Králové, Rokitanskeho 62, 50003 Hradec Králové, Czech Republic
Department of Neurology, Charles University in Prague, Faculty of Medicine in Hradec Králové and
University Hospital, Simkova 870, 50003 Hradec Králové, Czech Republic; Valismar@seznam.cz
Department of Chemistry, Faculty of Science, University of Hradec Králové, Rokitanskeho 62,
5
0003 Hradec Králové, Czech Republic; evzenie.n@seznam.cz
*
Correspondence: kamil.kuca@uhk.cz (K.K.); jmgranjeiro@gmail.com (J.M.G.);
Tel.: +420-603-289-166 (K.K.); +55-212-679-9834 (J.M.G.)
ꢀ
ꢁꢂꢀꢃꢄꢅꢆꢇ
Received: 28 September 2018; Accepted: 9 November 2018; Published: 12 November 2018
ꢀ
ꢁꢂꢃꢄꢅꢆ
Abstract: The present work aimed to compare the small, neutral and monoaromatic oxime,
isatin-3-oxime (isatin-O), to the commercial ones, pralidoxime (2-PAM) and obidoxime, in a search
for a new potential reactivator for acetylcholinesterase (AChE) inhibited by the pesticide paraoxon
(
AChE/POX) as well as a novel potential scaffold for further synthetic modifications. The multicriteria
decision methods (MCDM) allowed the identification of the best docking poses of those molecules
inside AChE/POX for further molecular dynamic (MD) studies, while Ellman’s modified method
enabled in vitro inhibition and reactivation assays. In corroboration with the theoretical studies,
our experimental results showed that isatin-O have a reactivation potential capable of overcoming
2-PAM at the initial moments of the assay. Despite not achieving better results than obidoxime,
this molecule is promising for being an active neutral oxime with capacity of crossing the blood–brain
barrier (BBB), to reactivate AChE/POX inside the central and peripheral nervous systems. Moreover,
the fact that isatin-O can also act as anticonvulsant makes this molecule a possible multipotent
reactivator. Besides, the MCDM method showed to be an accurate method for the selection of the
best docking poses generated in the docking studies.
Keywords: acetylcholinesterase; neutral oxime; molecular modeling; multicriteria decision making;
TOPSIS-AHP; Ellman’s method
Molecules 2018, 23, 2954; doi:10.3390/molecules23112954
www.mdpi.com/journal/molecules

Molecules 2018, 23, 2954
2 of 18
1
. Introduction
The intoxication by organophosphate compounds (OPs) remains a threat to human health,
with thousands of deaths every year [ ]. The toxicity of these compounds is due to the inhibition of the
1
enzyme acetylcholinesterase (AChE; EC 3.1.1.7), leading to the accumulation of the neurotransmitter
acetylcholine (ACh), and subsequent over-activation of cholinergic receptors in many parts of the body.
Poisoning by OPs causes physiologic consequences on the central and peripheral nervous systems
(
CNS and PNS). Thus, miosis, bronchorrhea, bronchoconstriction, bradycardia, emesis, skeletal muscle
contraction, tachycardia, seizures, respiratory arrest and other symptoms may occur, leading to
death [2].
The treatment for OPs poisoning is based on the administration of some drugs combined:
an anticholinergic agent (e.g., atropine), an anticonvulsant drug (e.g., diazepam) and a mono- or
bispyridinium AChE reactivator (e.g., pralidoxime, obidoxime, or trimedoxime) [
have investigated the mechanism of action of the oxime group in the reactivation of AChE inhibited
by OPs [ 17]. Due to its structural and molecular properties, oximes are considered the most potent
3]. Extensive studies
4–
reactivators for AChE inhibited by OPs up to the present moment. The high affinity for AChE
and nucleophilicity of these compounds allows the displacement of the OP from the catalytic site,
enabling the reactivation of AChE. Pralidoxime (2-PAM) (Figure 1) is a monoquaternary oxime and
one of the most employed as antidote today, although research indicates that bisquaternary oximes
are more effective in the reactivation process [18]. 2-PAM is commonly used in the United States,
while bispyridinium oximes, such as obidoxime (Figure 1), are used in European countries [19].
Figure 1. Structures 2-PAM, isatin-O and obidoxime.
Despite being used commercially, quaternary oximes still present serious disadvantages. Due to
their permanent charge, they poorly cross the blood–brain barrier (BBB), limiting their efficiency as
AChE reactivators in the CNS and PNS [20]. Moreover, there is no universal oxime. They have highly
variable efficiency depending on the nature of the OP [21]. For this reason, studies are focused
on looking for oximes that could be efficient against a larger number of OPs, conjugated with
an appropriate penetration in the BBB. In this sense, neutral oximes (Figure 2) have been proposed and
studied by several authors [11,18,22–25].
Isatin (1H-indole-2,3-dione) and its derivatives have been reported in the literature with vital
importance in medicinal chemistry. These molecules have presented pharmacological activities
such as anticancer, antiviral, antimicrobial, antifungal, anti-inflammatory, antioxidant, analgesic,
anticonvulsant, HIV reverse transcriptase inhibition, and antidiabetic [26–30]. Recently, they were also
used to design some new compounds for the treatment of neurodegenerative diseases and new AChE
inhibitors, demonstrating to also be able to interact with cholinesterases. One of the characteristics of
this group of molecules is the possibility of crossing the BBB [31,32].
Among the derivatives of isatin, isatin-3-oxime (isatin-O), presented in Figure 1, was identified as
an anticonvulsant [33,34]. This characteristic is essential for the treatment of OP poisoning, once current

Molecules 2018, 23, 2954
3 of 18
treatments require the use of the three combined drugs mentioned above (an anticonvulsant,
an anticholinergic and an oxime). However, the use of this combined therapy increases the
concentration of drugs in the organism, and may result in undesirable side effects. Thus, the use of
a multipotent drug with more possible actions, such as anticonvulsant and AChE reactivator, could
contribute to minimize this problem.
Figure 2. Structures of some neutral oximes reported in literature (1 [11], 2 [18] and 3–5 [22]).
In this way, aiming to contribute for the discovery of new active neutral oximes, that could also
act as anticonvulsants, and a potential scaffold for further synthetic modifications, we conducted in
silico and in vitro studies of the isatin-O on AChE from Electrophorus electricus inhibited by the OP
paraoxon (EeAChE/POX), and compared our results to those of the commercial oximes 2-PAM and
obidoxime. These references were chosen due to their efficacy as in vivo AChE reactivators and for
being the most commonly used oximes for the treatment of OP poisoning [20]. They have also been
used as standards of comparison in several published works [6,15,20,35–39]. Besides, the choice of
these oximes allowed us to compare the results with two structurally different references, 2-PAM,
which is more similar to isatin-O, and obidoxime with a larger molecular chain (see Figure 1). Another
critical aspect on this choice is the known fact that bisquaternary obidoxime is a more potent reactivator
for pesticide-inhibited AChE than monoquaternary 2-PAM [35].
In the in silico studies, we used docking and molecular dynamic techniques and a new approach
for evaluation and selection of poses generated in the molecular docking. Due to the large number
of poses produced in the molecular docking step, the process of evaluation and selection is complex.
Thus, we suggest the use of decision support methods that consider multicriteria to generate broader
and more reliable solutions. The use of an efficient method in this step is important because the chosen
pose is typically used to represent the behavior of the molecule in the docking studies and as initial
parameters for the molecular dynamic studies. Thereby, in this work, we suggest the adoption of
a multicriteria decision making methods (MCDM) to select the best poses.
For the in vitro studies, we used an Ellman’s [40] modified method [41]. Since its first publication,
this is the most common and relevant assay for investigating AChE activity [42
was developed in the early 1960s [40] and it is still in use today, with some further improving
modifications [41 44]. Despite some limitations eventually found, such as the lack of low detection
,43]. The method
,
limit and frequent background perturbations, this method has been extensively used [42] due to its
simplicity, accuracy, low cost and the large number of validated and published assays.

Molecules 2018, 23, 2954
4 of 18
2
. Results and Discussion
2
.1. Reactivation Tests
Figures 3 and 4 present the results of the reactivation tests for isatin-O, 2-PAM and obidoxime,
at concentrations of 10 and 100 µmol/L respectively.
Figure 3. Reactivation efficacy of the oximes for EeAChE/POX at 10 µmol/L.
Figure 4. Reactivation efficacy of the oximes for EeAChE/POX at 100 µmol/L.
The results of Ellman’s tests [40
,41] show that isatin-O can reactivate EeAChE/POX at 10 and
1
00
µ
mol/L. At 10 mol/L, it reached around 8% reactivation in the initial 10 min. At this concentration
µ
and time, 2-PAM reached close to 6% reactivation. This shows a good performance of isatin-O at short
times and low concentrations, better than the results achieved by 2-PAM. Considering literature reports
that 5% to 10% of reactivation is enough for the survival of the neurotoxic-intoxicated victims [45
–47],
this result points to isatin-O as a potential AChE reactivator. At 100 mol/L, despite showing lower
µ

Molecules 2018, 23, 2954
5 of 18
reactivation capacity over time, when compared to 2-PAM and obidoxime, isatin-O reached around
2
3% reactivation in the initial 120 min.
Among the oximes tested, the one with the highest potential for reactivation was obidoxime.
This result converges with other publications [
00 mol/L indicates that the reactivation reaches a higher level after 30 min (over 90%). After this time,
the reactivation rate decreases slightly. In the lower concentration range (10 mol/L), the reactivation
9,10,44,48]. The test performed with this oxime at
1
µ
µ
starts later and does not reach a maximum value before 120 min. Thus, at higher concentrations,
the reactivation is more effective, allowing to reach the optimal value in a shorter time. In silico studies
complemented and better explained the results of the in vitro tests and the molecular interactions
present in the enzymatic reactivation.
2
.2. Molecular Docking Studies
To validate the docking protocol, redocking studies were performed using 2-PAM from the
crystallographic structure as reference. The best conformation obtained (Figure 5), chosen according
to the criterion of better superposition of the non-hydrogen atoms, presented random mean square
deviation (RMSD) of 0.535 Å, intermolecular energy of
energy of 2.03 Kcal/mol. Since a RMSD value under 2.0 Å is considered acceptable [48], this result
validates the docking protocol used.
−
79.97 Kcal/mol, and hydrogen bonding
−
Figure 5. Best redocking pose.
After validation, molecular docking studies were performed for the oximes inside EeAChE/POX,
and most of the results obtained corroborated the in vitro assay. Table 1 presents a summary of the
docking results for the best poses selected for each oxime. The following parameters were considered:
(
1) distance between the oxygen atom of the oxime and the phosphorus atom of POX; (2) intermolecular
energy; (3) energy of interaction related to H-bonds; (4) residues involved in H-bond interactions
and, in the last column; and (5) the in vitro results of percentage of reactivation promoted by the

Molecules 2018, 23, 2954
6 of 18
oximes at 10 min, and at the concentration of 10
µmol/L. The choice of 10 min of reactivation time
was made to evaluate the initial action of the reactivator in a possible intoxication treatment [35].
The best poses for each oxime were chosen using the MCDM [49 51] hybrid method: Technique for
Order Preference by Similarity to Ideal Solution–Analytic Hierarchy Process (TOPSIS-AHP) [52 57].
–
–
The results are discussed in the next section. Obidoxime presented the lowest binding and H-bond
interaction energies. This suggests higher affinity for the active site in comparison to 2-PAM and
isatin-O. The highest energy values observed for 2-PAM point to an advantage for isatin-O over 2-PAM
in terms of potential reactivation at the first moments of intoxication and corroborate the in vitro
results. In addition, isatin-O showed the shortest O(oxime)-P(POX) distance. This means that this oxime
can get closer to POX than the commercial oximes, to trigger the reactivation reaction.
Table 1. Docking results for the oximes inside EeAChE/POX.
Intermolecular
Energy
H-Bond
Energy
(kcal/mol)
% Reactivation
(Mean in 10 min—
Conc. 10 µmol/L)
Distance
O(oxime)-P(POX) (Å)
Interaction
Residues
Oxime
(
kcal/mol)
Isatin-O
4.03
4.60
8.14
−75.22
−1.60
−11.54
−2.03
Ser125
6.37
24.55
4.13
Ser203 Tyr124
Tyr337 Asp74
Obidoxime
−122.48
−87.18
2-PAM
His447
Obidoxime presented the highest number of H-bond interactions, probably due to the two oximate
groups present on its structure. Results for the O(oxime)-P(POX) distance, intermolecular and H-bond
energies, and residues of interaction, point to this oxime as the best reactivator, followed by isatin-O,
and finally 2-PAM. This is in corroboration with the better reactivation results presented by obidoxime,
and suggest that isatin-O is a potential reactivator for AChE/POX. However, after 10 min, 2-PAM
presented better reactivation results than isatin-O. This fact may occur due to the interaction of 2-PAM
with one of the residues of the catalytic triad, His447, and also because 2-PAM is a positively charged
molecule, a fact that favors interactions in the active site and, in consequence, the stabilization of the
compound inside the enzyme. Figure 6 shows the best poses for isatin-O, obidoxime and 2-PAM.
These poses were selected using the MCDM [49–51] hybrid method TOPSIS-AHP [52–57].
Figure 6. Best docking poses for: (a) 2-PAM; (b) obidoxime; and (c) isatin-O.
2
.3. MCDM Method
This work adopted a hybrid multicriteria MCDM [49
–
51] hybrid method TOPSIS-AHP [52–57]
.
AHP method [55–57] was used to define the criteria weights and TOPSIS method [52–54] was used for
the general assessment of poses from the docking studies. The methodology used in the docking
calculations allowed the generation of 300 poses for each oxime studied (isatin-O, 2-PAM and
obidoxime), totalizing 900 poses. This shows the importance of having an appropriate method to
select the best poses, which will serve as the basis for evaluation of the interactions of these oximes in

Molecules 2018, 23, 2954
7 of 18
the active site, and further molecular dynamics simulations. Although the MCDM methods [49–51]
are efficient, 300 poses generate a very large evaluation matrix, resulting in extensive and laborious
calculations. Thus, to reduce the number of poses and to optimize the calculations, a screening
was done. The following elimination criteria were considered in the screening: (1) positive interaction
energy; (2) positive H-bond energy; (3) complete absence of interaction with active site residues;
and (4) similarity. In addition, from the remaining poses, one per docking run was selected to remain
in the evaluation, considering the lowest O(oxime)-P(POX) distance, and the lowest interaction energy.
As 10 docking runs were done per each oxime, at least the best 10 poses remained to be evaluated.
The evaluation steps described in the TOPSIS methodology [52
the performances of the poses were obtained using the docking method described. A decision matrix
DM) was constructed for each oxime, as shown in Table 2, considering the following criteria: distance
–54] were followed. First,
(
O(oxime)-P(POX), intermolecular energy, H-bond energy and interaction residues (H-bonds). Table 2
reveals the values for the criteria weights as well as when the criterion is increasing or decreasing,
represented by max and min values, respectively. The poses with better performances, according to the
evaluation using the hybrid MCDM method TOPSIS-AHP [52–57], are highlighted and shown in bold.
Table 2. Decision matrix (isatin-O and obidoxime). The poses with better performances are shown
in bold.
Distance
O-P (Å)
Intermolecular
Energy (kcal/mol)
H-Bond Energy
(kcal/mol)
Interaction
Residues
Criterion
Max/Min
Weight
Min
0.633
Min
0.228
Min
0.044
Max
0.095
Isatin-O
−81.13
−94.18
−84.51
−81.33
−93.39
−71.62
−76.95
−78.03
−92.04
−85.00
Obidoxime
−123.99
−125.10
−103.54
−111.45
−122.32
−122.76
−118.75
−122.48
−121.38
−111.4
Dock1
Dock2
Dock3
Dock4
Dock5
Dock6
Dock7
Dock8
Dock9
Dock10
5.19
4.50
3.75
5.76
4.68
5.44
3.76
4.50
4.60
4.50
−4.92
−2.65
−0.6
2
2
1
3
3
2
1
3
3
2
−7.76
−2.53
−2.25
−2.18
−0.96
−3.77
−0.24
Dock1
Dock2
Dock3
Dock4
Dock5
Dock6
Dock7
Dock8
Dock9
Dock10
5.28
4.62
5.42
5.3
5.29
5.15
5.3
4.6
5.28
5.12
−8.78
−7.71
−5.33
−11.7
−5.20
−8.67
−7.22
−11.54
−7.73
−10.23
4
3
2
3
3
4
3
4
3
2
The weights of the criteria defined for the evaluation were determined using the AHP
method [55 57]. Four specialists (authors) evaluated the importance of the criteria presented.
–
The weight evaluation matrix was generated with the geometric mean of the evaluations of each
specialist, using the aggregation of individual judgments (AIJ), which transforms individual pairwise
comparison matrices (PCMs) into a PCM group from which the group priorities are then derived [58].
Table 3 presents the individual PCMs of the four specialists who participated in the evaluation of the
criteria, the PCM of the group, calculated with the AIJ aggregation method [59], and the CRs of the
matrices. As can be seen, all the evaluation matrices, both individual and of the group, presented
CR < 0.1, a result which confirms the good quality and approves the evaluation matrices. Therefore,

Molecules 2018, 23, 2954
8 of 18
the values of the weights calculated with the AHP method [55
–
57] present in Table 3 could be used
with reliability in the TOPSIS method [52–54] for evaluation of the poses.
Table 3. Pairwise Comparison Matrices (PCMs).
DM1
Crit 1
Crit 2
Crit 3
Crit 4
DM2
Crit 1
Crit 2
Crit 3
Crit 4
Crit 1
Crit 2
Crit 3
Crit 4
1
5
1
1/5
1/4
9
5
1
3
7
4
1/3
1
Crit 1
Crit 2
Crit 3
Crit 4
1
4
1
1/7
1/4
9
7
1
4
7
4
1/4
1
1/5
1/9
1/7
1/4
1/9
1/7
CR = 0.09
Crit 2
CR = 0.09
Crit 2
DM3
Crit 1
Crit 3
Crit 4
DM4
Crit 1
Crit 3
Crit 4
Crit 1
Crit 2
Crit 3
Crit 4
1
5
1
1/5
1/3
9
5
1
4
7
3
Crit 1
Crit 2
Crit 3
Crit 4
1
4
1
1/5
1/4
8
5
1
3
6
4
1/3
1
1/5
1/9
1/7
1/4
1/8
1/6
1
4
1
CR = 0.08
Crit 2
CR = 0.08
GrPCM
Crit 1
Crit 3
Crit 4
W = Weights
i
Crit 1
Crit 2
Crit 3
Crit 4
1
4.47
1
0.18
0.27
8.74
5.44
1
6.74
3.72
0.29
1
0.633
0.228
0.044
0.095
0.22
0.11
0.15
3.46
CR = 0.083
Crit 1, Distance O(oxime)-P(POX); Crit 2, Intermolecular energy; Crit 3, H-bond energy; Crit 4, Interaction residues;
DM, decision maker/expert; GrPCM, Group pairwise comparison matrix.
All calculations described in the methodology for the evaluation of poses were done using the
TOPSIS method [52–55] with spreadsheets elaborated in excel software©. Figure 7 shows the results
of the similarity coefficient calculations, for s = 2, of isatin-O and obidoxime. It was thus possible
to select the best pose for each molecule, since the MCDM method employed generates, as a result,
ordered poses, from the closest to the most distant solution, allowing the identification of the ideal
solution. As 2-PAM was submitted to redocking, with its conformation present in the crystalline
structure removed from the PDB, it was not necessary to carry out the selection of pose calculations,
since, in this case, the selection met the redocking criterion. The best poses of each oxime studied
were selected, as presented in Table 2 and Figures 6 and 7, and then used in the further molecular
dynamic simulations.

Molecules 2018, 23, 2954
9 of 18
Figure 7. Results for the evaluation of poses through the hybrid MCDM TOPSIS-AHP method.
Left): Isatin-O; (Right): Obidoxime.
(
2
.4. Molecular Dynamic Study
MD simulations were performed with the best poses obtained from docking studies. Results show
that, for all systems, the total energy tends to stabilize after 2.5 ns of simulation, with the average
5
values for all complexes around
−
9.82
×
10 kJ/mol, as shown in the total energy plots for the complex
EeAChE-POX/isatin-O in Figure 8. In addition, the temporal RMSD plots for all systems, shown in
Figure 9, confirm these results. All values obtained were below 0.3 nm (3 Å) for the protein, and below
0
.05 nm (0.5 Å), for the ligands, except for obidoxime.
Figure 8. Energy plot for the complex EeAChE/POX/isatin-O during 20 ns of MD simulation.

Molecules 2018, 23, 2954
10 of 18
Figure 9. RMSD plots for the complexes EeAChE/POX/ligands during 20 ns of MD simulation.
Studies of H-bond prevalence among enzyme and ligands were performed. Results suggest that
the H-bond with residue Ser125 is an important contribution for the stabilization of isatin-O inside
EeAChE-POX. This was observed in both docking and MD studies. Asp74 plays the same role in the
complex EeAChE-POX/Obidoxime. Figure 10 shows the H-bond profiles for all systems during the
simulation time. It is important to notice that isatin-O presented a higher average number of H-bonds,
with a higher number of interacting residues than Obidoxime and 2-PAM. Besides, isatin-O was the
only compound presenting at least one H-bond during the whole simulation time. The results obtained
for average number of H-bond interactions and main residues of interaction for isatin-O, 2-PAM and
Obidoxime, are summarized in Table 4.
Figure 10. H-bond prevalence for the systems EeAChE/POX/oximes.

Molecules 2018, 23, 2954
11 of 18
Table 4. Summary of MD results for all complexes EeAChE/POX/ligands. The interacting residues
observed also in docking studies are shown in red.
Oxime
Average H-Bond Number
Interaction Residues
Leu76
Tyr77
Isatin-O
3
Thr83
Asn89
Ser125
Asp74
Thr83
Asn89
Glu202
Obidoxime
2
1
2
-PAM
His441
3
. Experimental Section
3
.1. Synthesis of the Oximes
Isatin-O was synthesized as follows [26
,
34]: (i) 1 mmol of the isatin was dissolved in 1 mL of
water, followed by addition of 2 mmol hydroxylamine hydrochloride (NH OH.HCl); (ii) the system
2
◦
was heated in a microwave Biotage Initiator at 120 C for 30 min (variable power, pre-agitation of 60 s,
high irradiation level); (iii) the reaction was monitored through thin layer chromatography (eluent
3:7 ethyl acetate: hexane, UV exposure and basic potassium permanganate solution); and (iv) the
product was isolated through vacuum filtration, and washed with ice water, leading to the pure
oxime (yield 98%). The structure and purity of the product was confirmed through spectroscopic data.
1
H-NMR (DMSO-d , δ-ppm, 400 MHz): 6.88 (d, 1H, 7.78 Hz), 7.02 (t, 1H, 7.58 Hz), 7.35 (t, 1H, 7.63 Hz),
6
7
1
1
.95 (d, 1H, 7.49 Hz), 10.68 (s, 1H), 13.28 (s, 1H); 13C-NMR/DEPT-Q (DMSO-d6,
δ
-ppm, 100 MHz):
+
10.70, 116.41, 122.49, 127.53, 132.49, 143.07, 144.69, 164.99; GC/MS-CI (CH ): MW 162, [M + H]
63 m/z; MP: 234–236 C (decomposition). Sixty-five milligrams (with 50% yield) of obidoxime
4
◦
1
dichloride were synthesized and purified as described before in the literature [46,60]. H-NMR
(
1
DMSO-d6,
3.09 (s, 2H); 13C-NMR (DMSO-d6,
purchased from Sigma-Aldrich Brazil (São Paulo, Brazil).
δ
-ppm, 400 MHz): 6.15 (s, 4H), 8.26 (d, 4H, 6.24 Hz), 8.43 (s, 2H), 9.14 (d, 4H, 6.37 Hz),
δ-ppm, 100 MHz): 86.17, 124.39, 144.89, 145.63, 150.90. 2-PAM was
3
.2. Modified Ellman Method
The Ellman method was employed on the biochemical evaluation of AChE activity, being
a classic method of enzymatic evaluation [40]. In this study, the method was adapted to microscale
to work with small doses of OPs as well as to reduce the risks of accidental intoxication [41].
In addition, scale reduction also provided significant savings in materials and reagents. Ellman’s
method were conducted in triplicate, in three different assays, by at least three different operators,
◦
measured at 24 ± 2 C. All disposable materials and glassware in contact with OP compounds were
decontaminated with aqueous solution containing 10% w/v NaOH and 10% w/v NaClO for 48 h at
room temperature before correct destination and cleaning.
3
.2.1. Chemicals
Acetylthiocholine iodide, 5,5 -dithiobis-(2-nitrobenzoic) acid (DTNB), lyophilized EeAChE
0
(
(
1000 U per mg protein, Type V-S, C2888), 2-PAM iodide, DMF (dry, oxygen-free sealed bottle), DMSO
biological grade, dry, oxygen-free sealed bottle), triethylamine (dry, oxygen-free sealed bottle), acetone,
4
-pyridinecarboxaldehyde, sodium hydroxide (pellets), sodium phosphate monobasic hydrate, and
sodium phosphate dibasic dihydrate were purchased from Sigma-Aldrich Brazil (São Paulo, Brazil).
Absolute ethanol was purchased from Tedia Brazil (Rio de Janeiro, Brazil). Deuterated solvents

Molecules 2018, 23, 2954
12 of 18
(CDCl and DMSO-d ), containing tetramethylsilane as internal standard, were purchased from CIL
3 6
(Tewksbury, MA, USA). Bovine Serum Albumin (BSA), purchased from Prime Alert BioDetection
System, GenPrime, Spokane (Washington, DC, USA), were provided by the biological defense section
of the Institute for Chemical, Biological, Radiological and Nuclear Defense (IDQBRN). Technical grade
sodium hypochlorite purchased from VETEC (Rio de Janeiro, RJ, Brasil) was provided by the chemical
defense decontamination team of the IDQBRN. Purified water was obtained from Millipore Milli-Q
◦
system (18.2 M
Ω
cm at 25 C, Millipore Brazil, São Paulo, Brazil). Biotage Initiator 8 (Charlotte,
NC, USA) was used for the synthesis of all oximes. TLC aluminum plates, coated with silica gel F254,
were purchased from Merck Brazil (São Paulo, Brazil). Camag TLC-MS (AuTeC, São Paulo, Brazil)
interface was used to follow up reactions. NMR spectra was obtained from Varian Unity 400 MHz and
1
13
Bruker Advance 400 MHz, and referred to tetramethylsilane for H and C NMR spectra. GC-MS data
were obtained from an Agilent 6890 GC system equipped with a 5975 C mass spectrometer detector.
Kasvi 96-wells microplates were purchased from Kasvi Brasil (São José dos Pinhais, Paraná, Brazil),
Gilson single channel were from Gilson Inc. (Middleton, WI, USA) and Eppendorf 8-channel were
from Eppendorf Brasil (São Paulo, Brazil).
3
.2.2. Inhibition Assay
In a 96-well microplate (final volume per well of 200
µ
L) the following was added per well:
L PBS; and 10 L POX
mol/L per well, positive control, absorbance L ). After 10 min of incubation, 20 L of
7
2
1
0
00
µ
L AChE 2.14 U/mL (0.75 U/mL per well); 80
mol/L (11
mmol/L ATCI were added and, after additional 10 min, absorbance was read at 412 nm. PBS (10
µL DTNB 0.4 mg/mL; 20
µ
µ
µ
µ
µ
i
µL)
was used as negative control (absorbance L ). AChE inhibition was calculated using Equation (1):
0
%
I = [(L − L )/L ] × 100
(1)
0
i
0
where %I is the inhibition percentage, L is the absorbance without inhibitor, and L is the absorbance
0
i
with inhibitor.
3
.2.3. Reactivation Assay
In a 96-well microplate (final volume per well of 200
L AChE 2.14 U/mL (0.75 U/mL per well); 80
mol/L per well, positive control). After 10 min of incubation, 20
test molecule were added, followed by further 10 min incubation. Then, 20
µ
L) the following was added per well:
7
0
µ
µ
L DTNB 0.4 mg/mL; and 10
L of standard antidote or
L of 1 mmol/L ATCI
r
) was read after 10 min. AChE reactivation was calculated using
µL POX 200 µmol/L
(11
µ
µ
µ
were added and the absorbance (L
Equation (2):
%
R = [(Lr − Li)/(L − Li)] × 100
(2)
0
where %R is the reactivation percent, L is the absorbance without inhibitor, L is the absorbance with
0
i
inhibitor, and Lr is the absorbance after addition of reactivator.
3
.3. Molecular Modeling Studies
Docking and MD studies were carried out to verify the binding modes of isatin-O inside inhibited
EeAChE and compared its reactivation potential to the commercial oximes 2-PAM and Obidoxime.
The model of EeAChE inhibited by POX was used in this work to be as close as possible to the
experimental in vitro test. It was constructed using human AChE (HssAChE) inhibited by POX and
complexed with 2-PAM (PDB code: 5HFA) as template. The primary (FASTA) sequences of HssAChE
and EeAChE (PDB code: 1C2O) were aligned and the different residues mutated using the software
spdbviewer [61] to obtain the model of EeAChE inhibited by POX, and complexed with 2-PAM.
Target and template presented 89% of homological identity and 100% of the active site residues
conserved. The model was further validated using the server PDBSum (www.ebi.ac.uk/pdbsum).
The 3D structures of more stable and active conformations of each oxime (2-PAM [62], obidoxime [63
]

Molecules 2018, 23, 2954
13 of 18
and isatin-O [34]) were constructed through the program PC Spartan 08® [64] and their partial atomic
charges calculated through the RM1 (Recife Model 1) semi-empirical method [65].
3
.3.1. Molecular Docking
The software Molegro Virtual Docker (MVD)® [66] was used to perform docking studies through
the algorithm MolDock Score, an adaptation of the algorithm Differential Evolution (DE) [67].
The oximes were docked in the model after a redocking procedure to validate the methodology.
The RMSD was calculated using 2-PAM as reference. The binding site was limited to a sphere with
a radius of 11 Å and residues within a 10 Å radius were considered flexible. Due to the stochastic nature
of the docking algorithm, about 10 runs were done for each compound, with 30 configurations (poses)
returned for evaluation. The best pose of each compound was selected according to the following
criteria: distance between the P atom of POX and the O atom of the oxime, interaction energy between
the oxime and inhibited EeAChE, energy involved on hydrogen bonds and total number of AChE
residues interacting with the oxime. To select the best poses of the docking study, multicriteria decision
methods (MCDM) [49
–51] were employed. The pairwise comparison method (AHP) [55–57] was used
to calculate the criteria weights and TOPSIS [52–54] was used for ranking the best poses.
3
.3.2. Molecular Dynamics
The poses chosen from the docking studies were parameterized for the OPLS/AA forcefield
available in the GROMACS 5.1.4 program [68], and the parameters and topologies were
obtained from the software AnteChamber PYthon Parcer InterfacE (ACPYPE) [69]. The complexes
3
EeAChE-POX/oxime were simulated using GROMACS 5.1.4 [68] package in a cubic box (941.59 nm )
containing approximated 28,522 spc216 water molecules with periodic boundary conditions.
The minimization steps were steepest descent with position restrained (PR) of ligands and protein,
with a convergence criterion of 100.00 Kcal/mol.Å, steepest descent without PR to flexibilize the system,
conjugate gradients (CG), and L-BFGS (limited-memory Broyden–Fletcher–Goldfarb–Shanno [24]),
until a minimum of energy of 1.00 Kcal/mol.Å. After that, two steps of equilibration were done.
The first one under constant number of particles, volume and temperature (NVT) and the second
under constant number of particles, pressure and temperature (NPT). The minimized complexes were
submitted to MD simulations in two parts. First, 500 ps of MD were done at 310 K, with PR for
the entire system, except the water molecules, to ensure a balance of the solvent molecules around
the residues of the enzyme. After, 20,000 ps of MD were done at 310 K without any restriction,
using 2 fs of integration time and a cut-off of 10 Å for long-distance interactions. Counter ions were
added to neutralize the whole systems. The trajectories generated after the optimization and MD
steps were visualized on VMD [70] software. Plots of total energy, distance, variation of RMSD and
H-bonds formed during the MD simulation were generated on the Grace program (Version 5.1.25,
http://plasma-gate.weizmann.ac.il/Grace/). Pictures of MD frames during the MD simulations were
generated in the PyMOL program [71].
3
.4. MCDM Method
The MCDM method employed for the choice of the best docking poses is presented in the
Supplementary Materials [49–59,72,73].
4
. Conclusions
In this work, molecular modeling, MCDM methods, and biochemical tests were performed to
evaluate the neutral oxime isatin-O as a potential reactivator or scaffold for AChE/POX. Two classical
oximes, 2-PAM and obidoxime were selected to serve as references in the studies. Docking and MD
studies pointed to isatin-O as a potential reactivator of AChE/POX. Both methods showed isatin-O
with higher reactivation potential than 2-PAM, although it did not exceed the obidoxime results.
These data suggest the convergence and increasing confidence in the results.

Molecules 2018, 23, 2954
14 of 18
In the same direction, Ellman’s tests also pointed to isatin-O as a potential reactivator of
AChE/POX. This neutral molecule achieved a reactivation of about 23% after 120 min at 100
and close to 10% at initial instants, demonstrating activity. At lower concentration, 10
µ
mol/L
µmol/L,
it reached approximately 10% reactivation from the initial instants of the assay and remained
stable during the time. As reported in the literature [45 47], these percentages are sufficient to keep
–
a poisoning victim alive. Comparing with traditional reference oximes, in the initial minutes of the test,
the results of isatin-O slightly exceeds 2-PAM, being overcome by obidoxime. However, the percentage
of reactivation of isatin-O did not exceed the results of the two classical oximes in longer times.
Although not as efficient as obidoxime, isatin-O and possible derivatives were expected to exhibit
higher capacity for BBB penetration and demonstrate promising in vivo reactivation ability as a result
of their nonquaternary structures [23]. Moreover, they can act as anticonvulsants, making them possible
multipotent reactivators. These results may indicate a starting point to a novel potential scaffold for
further synthetic modifications and development of more efficient centrally acting reactivators for
OP poisoning.
Regarding the adopted poses assessment methodology in the docking studies, the use of the
hybrid MCDM method TOPSIS-AHP [52–57] contributed to improving the molecular modeling
techniques. The use of this method is unprecedented in this area of study. Its application showed to be
advantageous related to the conventional forms of selection of the best poses generated in the docking
studies, since it considers multiple criteria of selection simultaneously and presents at the end the
ordering of the best poses.
The paired comparison AHP method was used at the stage where the TOPSIS method is less
efficient at the evaluation of criteria weights. Paired comparison using the Saaty scale of the AHP
method revealed to be proper for the evaluation of the criteria weights. The TOPSIS method, in its
turn, was used at the stage where it is most efficient, in the general evaluation of the decision matrix.
Therefore, the hybrid method adopted used the strengths of each technique, generating an adequate
evaluation and selection of the poses obtained from docking studies.
Supplementary Materials: The supplementary materials are available online, MCDM method.
Author Contributions: R.L.d.P., S.F.A.C., J.M.G. and K.K. conceived and designed the project; S.F.A.C., A.B.C.S.
synthesized the oximes; R.L.d.P., S.F.A.C., A.B.C.S. and E.N. designed and conducted in vitro experiments and
wrote the corresponding part of the article; J.S.F.D.d.A., T.C.C.F. and A.S.G. designed and conducted in silico
experiments and wrote the corresponding part of the article. R.L.d.P., J.S.F.D.d.A., K.K., M.V. and T.C.C.F. finalized
the paper.
Funding: This work was funded by Military Institute of Engineering, Brazilian financial agencies CNPq (Grant No.
3
06156/2015-6) and FAPERJ (Grant No. E-02/202.961/2017), Excellence project FIM UHK.; Organisation for the
Prohibition of Chemical Weapons—OPCW “Research Projects Supports Programme” L/ICA/ICB/201062/15,
by University of Hradec Kralove programs (no. SV2103-2017 and VT2201-2018) and University of Hradec
Králové Long-term development plan. This paper was also supported by the research project MH CZ-DRO
(UHHK 00179906).
Conflicts of Interest: The authors declare no conflict of interest. The founding sponsors had no role in the design
of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, and in the
decision to publish the results.
References
1.
2.
3.
4.
Eddleston, M.; Buckley, N.A.; Eyer, P.; Dawson, A.H. Management of acute organophosphorus pesticide
poisoning. Lancet 2008, 371, 597–607. [CrossRef]
Schecter, W.P. Cholinergic symptoms due to nerve agent attack: A strategy for management. Clin. N. Am.
2
004, 22, 579–590. [CrossRef] [PubMed]
Cannard, K. The acute treatment of nerve agent exposure. J. Neurol. Sci. 2006, 249, 86–94. [CrossRef]
PubMed]
[
Van Helden, H.P.; Busker, R.W.; Melchers, B.P.C.; Bruijnzeel, P.L.B. Pharmacological effects of oximes:
How relevant are they. Arch. Toxicol. 1996, 70, 779–786. [CrossRef] [PubMed]

Molecules 2018, 23, 2954
15 of 18
5
.
.
Kassa, J. Review of oximes in the antidotal treatment of poisoning by organophosphorus nerve. J. Toxicol.
Clin. Toxicol. 2002, 40, 803–816. [CrossRef] [PubMed]
Worek, F.; Thiermann, H.; Szinics, L.; Eyer, P. Kinetic analysis of interactions between human
acetylcholinesterase, structurally different organophosphorus compounds and oximes. Biochem. Pharmacol.
6
2
004, 68, 2237–2248. [CrossRef] [PubMed]
7
.
Kim, T.H.; Ku cˇ a, K.; Jun, D.; Jung, Y.S. Design and synthesis of new bis-pyridinium oxime reactivators
for acetylcholinesterase inhibited by organophosphorus nerve agents. Bioorg. Med. Chem. Lett. 2005, 15,
2
914–2917. [CrossRef] [PubMed]
8
9
1
1
.
.
Brunton, L.L.; Lazo, J.S.; Parker, K.L. The Pharmacological Basis of Therapeutics, 11th ed.; McGraw-Hill, Medical
Publishing Division: New York, NY, USA, 2006.
Milatovi c´ , D.; Jokanovi c´ , M. Pyridinium Oximes as Cholinesterase Reactivators in the Treatment of OP
Poisoning. In Handbook of Toxicology of Chemical Warfare Agents; Elsevier Inc.: London, UK, 2009; pp. 985–996.
0. Ku cˇ a, K.; Musílek, K.; Jun, D.; Bajgar, J.; Kassa, J. Novel Oximes. In Handbook of Toxicology of Chemical Warfare
Agents; Elsevier Inc.: London, UK, 2009; pp. 997–1021.
1. Koning, M.C.; Van Grol, M.; Noort, D. Peripheral site ligand conjugation to a non-quaternary oxime enhances
reactivation of nerve agent-inhibited human acetylcholinesterase. Toxicol. Lett. 2011, 206, 54–59. [CrossRef]
[PubMed]
1
1
2. Musílek, K.; Dolezal, M.; Gunn-Moore, F.; Ku cˇ a, K. Design, evaluation and structure-Activity relationship
studies of the AChE reactivators against organophosphorus pesticides. Med. Res. Rev. 2011, 31, 548–575.
[
CrossRef] [PubMed]
3. Saint-André, G.; Kilachyna, M.; Kodepely, S.; Louise-Leriche, L.; Gillon, E.; Renard, P.Y.; Nachon, F.; Baati, R.;
Wagner, A. Design, synthesis and evaluation of new -nucleophiles for the hydrolysis of organophosphorus
nerve agents: Application to the reactivation of phosphorylated acetylcholinesterase. Tetrahedron 2011, 67,
352–6361. [CrossRef]
α
6
1
4. Chambers, J.E.; Meek, E.C.; Chambers, H.W. Novel brain-penetrating oximes for reactivation of cholinesterase
inhibited by sarin and VX surrogates. Ann. N. Y. Acad. Sci. 2016, 1374, 52–58. [CrossRef] [PubMed]
5. Winter, M.; Wille, T.; Musílek, K.; Ku cˇ a, K.; Thiermann, H.; Worek, F. Investigation of the reactivation kinetics
of a large series of bipyridinium oximes with organophosphate-inhibited human acetylcholinesterase.
Toxicol. Lett. 2016, 244, 136–142. [CrossRef] [PubMed]
1
1
6. Matos, K.S.; Mancini, D.T.; Cunha, E.F.F.; Ku cˇ a, K.; França, T.C.C.; Ramalho, T.C. Molecular Aspects of the
Reactivation Process of Acetylcholinesterase Inhibited by Cyclosarin. J. Braz. Chem. Soc. 2011, 10, 1999–2004.
[CrossRef]
1
7. Matos, K.S.; Cunha, E.F.F.; Gonçalves, A.S.; Wilter, A.; Ku cˇ a, K.; França, T.C.C.; Ramalho, T.C.
First principles calculations of thermodynamics and kinetic parameters and molecular dynamics simulations
of acetylcholinesterase reactivators: Can mouse data provide new insights into humans? J. Biomol. Struct. Dyn.
2
012, 30, 546–558. [CrossRef] [PubMed]
1
1
2
2
2
8. Koning, M.C.; Joonsen, M.J.A.; Noort, D.; Van Zuylen, A.; Tromp, M.C. Peripheral site ligand-oxime
conjugates: A novel concept towards reactivation of nerve agent-inhibited human acetylcholinesterase.
Bioorg. Med. Chem. 2011, 19, 588–594. [CrossRef] [PubMed]
9. Luo, C.; Tong, M.; Chilukuri, N.; Brecht, K.; Maxwell, D.M.; Saxena, A. An in vitro comparative study on the
reactivation of nerve agent-inhibited guinea pig and human acetylcholinesterases by oximes. Biochemistry
2
009, 46, 11771–11779. [CrossRef] [PubMed]
0. Mercey, G.; Verdelet, T.; Renou, J.; Kliachyna, M.; Baati, R.; Nachon, F.; Jean, L.; Renard, P.Y. Reactivators
of Acetylcholinesterase Inhibited by Organophosphorus Nerve Agents. Acc. Chem. Res. 2012, 45, 756–766.
[CrossRef] [PubMed]
1. Renou, J.; Dias, J.; Mercey, G.; Vendelet, T.; Rousseau, C.; Gastellier, A.J.; Arboléas, M.; Loiodice, M.T.;
Baati, R.; Jean, L.; et al. Synthesis and in vitro evaluation of donepezil-based reactivators and analogues for
nerve agent-inhibited human acetylcholinesterase. RSC Adv. 2016, 6, 17929–17940. [CrossRef]
2. Kliachyna, M.; Santoni, G.; Nussbaum, V.; Renou, J.; Sanson, B.; Colletier, J.P.; Baati, R. Design, synthesis and
biological evaluation of novel tetrahydroacridine pyridine aldoxime and amidoxime hybrids as efficient
uncharged reactivators of nerve agent inhibited human acetylcholinesterase. Eur. J. Med. Chem. 2014, 78,
4
55–467. [CrossRef] [PubMed]

Molecules 2018, 23, 2954
16 of 18
2
2
2
2
3. Wei, Z.; Liu, Y.; Wang, Y.; Li, W.; Zhou, X.; Zhao, J.; Li, S. Novel nonquaternary reactivators showing
reactivation efficiency for soman-inhibited human acetylcholinesterase. Toxicol. Lett. 2016, 246, 1–6. [CrossRef]
PubMed]
4. Almeida, J.S.F.D.; Cuya Guizado, T.R.; Guimarães, A.P.; Ramalho, T.C.; Gonçalves, A.S.; de Koning, M.C.;
França, T.C.C. Docking and molecular dynamics studies of peripheral site ligand–oximes as reactivators of
sarin-inhibited human acetylcholinesterase. J. Biomol. Struct. Dyn. 2016, 34, 2632–2642. [CrossRef] [PubMed]
5. Silva, J.A.V.; Modesto-Costa, L.; Koning, M.C.; Borges, I., Jr.; França, T.C.C. Theoretical NMR
and conformational analysis of solvated oximes for organophosphates-inhibited acetylcholinesterase.
J. Mol. Struct. 2018, 1152, 311–320. [CrossRef]
[
6. Nassar, M.Y.; Attia, A.S.; Adawy, S.; El-Shahat, M.F. Novel Isatinoxime Molybdenum and Chromium
Complexes: Synthesis, Spectroscopic, and Thermal Characterization. J. Mol. Struct. 2012, 1026, 88–92.
[CrossRef]
2
2
2
7. Liang, C.; Xia, J.; Lei, D.; Li, X.; Yao, Q.; Gao, J. Synthesis, in Vitro and in Vivo Antitumor Activity of
Symmetrical Bis-Schiff Base Derivatives of Isatin. Eur. J. Med. Chem. 2014, 74, 742–750. [CrossRef] [PubMed]
8. Sai Prathima, P.; Bikshapathi, R.; Rao, V.J. Synthesis of Isatin Derivatives under Metal Free Conditions Using
Hypervalent Iodine. Tetrahedron Lett. 2015, 56, 6385–6388. [CrossRef]
9. Ozgun, D.O.; Yamali, C.; Gul, H.I.; Taslimi, P.; Gulcin, I.; Yanik, T.; Supuran, C.T. Inhibitory Effects of Isatin
Mannich Bases on Carbonic Anhydrases, Acetylcholinesterase, and Butyrylcholinesterase. J. Enzyme Inhib.
Med. Chem. 2016, 31, 1498–1501. [CrossRef] [PubMed]
3
3
3
3
0. Melis, C.; Meleddu, R.; Angeli, A.; Distinto, S.; Bianco, G.; Capasso, C.; Cottiglia, F.; Angius, R.; Supuran, C.T.;
Maccioni, E. Isatin: A Privileged Scaffold for the Design of Carbonic Anhydrase Inhibitors. J. Enzyme Inhib.
Med. Chem. 2017, 32, 68–73. [CrossRef] [PubMed]
1. Bhattacharya, S.K.; Clow, A.; Przyborowska, A.; Halket, J.; Glover, V.; Sandler, M. Effect of Aromatic Amino
Acids, Pentylenetetrazole and Yohimbine on Isatin and Tribulin Activity in Rat Brain. Neurosci. Lett. 1991
32, 44–46. [CrossRef]
,
1
2. Rane, R.; Karunanidhi, S.; Jain, K.; Shaikh, M.; Hampannavar, G.; Karpoormath, R. A Recent Perspective
on Discovery and Development of Diverse Therapeutic Agents Inspired from Isatin Alkaloids. Curr. Top.
Med. Chem. 2016, 16, 1262–1289. [CrossRef] [PubMed]
3. Pinto, A.C.; Lapis, A.A.M.; da Silva, B.V.; Bastos, R.S.; Dupont, J.; Neto, B.A.D. Pronounced Ionic Liquid Effect
in the Synthesis of Biologically Active Isatin-3-Oxime Derivatives under Acid Catalysis. Tetrahedron Lett.
2
008, 49, 5639–5641. [CrossRef]
3
4. Laxmi, K. Theoretical Approach on Structural Aspects of Antiepileptic Agent Indoline-2, 3-Dione-3-Oxime
by Arguslab 4 Software. J. Appl. Chem. 2014, 2, 92–101.
3
5. Jun, D.; Musilova, L.; Musílek, K.; Ku cˇ a, K. In Vitro Ability of Currently Available Oximes to Reactivate
Organophosphate Pesticide-Inhibited Human Acetylcholinesterase and Butyrylcholinesterase. Int. J. Mol. Sci.
2
011, 12, 2077–2087. [CrossRef] [PubMed]
3
3
6. Bharate, S.B.; Guo, L.; Reeves, T.E.; Cerasoli, D.M.; Thompson, C.M. Bisquaternary Pyridinium Oximes:
Comparison of in Vitro Reactivation Potency of Compounds Bearing Aliphatic Linkers and Heteroaromatic
Linkers for Paraoxon-Inhibited Electric Eel and Recombinant Human Acetylcholinesterase. Bioorg. Med. Chem.
2
010, 18, 787–794. [CrossRef] [PubMed]
7. Costa, M.D.; Freitas, M.L.; Soares, F.A.A.; Carratu, V.S.; Brandão, R. Potential of Two New Oximes
in Reactivate Human Acetylcholinesterase and Butyrylcholinesterase Inhibited by Organophosphate
Compounds: An in Vitro Study. Toxicol. In Vitro 2011, 25, 2120–2123. [CrossRef] [PubMed]
8. Worek, F.; Thiermann, H. The Value of Novel Oximes for Treatment of Poisoning by Organophosphorus
Compounds. Pharmacol. Ther. 2013, 139, 249–259. [CrossRef] [PubMed]
3
3
9. Krishnan, J.K.S.; Arun, P.; Appu, A.P.; Vijayakumar, N.; Figueiredo, T.H.; Braga, M.F.M.; Baskota, S.;
Olsen, C.H.; Farkas, N.; Dagata, J.; et al. Intranasal Delivery of Obidoxime to the Brain Prevents Mortality
and CNS Damage from Organophosphate Poisoning. Neurotoxicology 2016, 53, 64–73. [CrossRef] [PubMed]
0. Ellman, G.L.; Courtney, K.D.; Andres, V., Jr.; Featherstone, R.M. A new and rapid colorimetric determination
of acetylcholinesterase activity. Biochem. Pharmacol. 1961, 7, 88–95. [CrossRef]
4
4
1. Cavalcante, S.F.A.; Kitagawa, D.A.S.; Rodrigues, R.B.; Cardozo, M.; de Paula, R.L.; de Correa, A.B.A.;
Simas, B.C. Straightforward, economical procedures for microscale Ellman’s test for cholinesterase inhibition
and reactivation. Quim. Nova 2018, 41, 1192–1195. [CrossRef]

Molecules 2018, 23, 2954
17 of 18
4
4
2. Pohanka, M.; Hrabinova, M.; Kuca, K.; Simonato, J.P. Assessment of Acetylcholinesterase Activity Using
Indoxylacetate and Comparison with the Standard Ellman’s Method. Int. J. Mol. Sci. 2011, 12, 2631–2640.
CrossRef] [PubMed]
3. Järvinen, P.P.; Fallarero, A.; Gupta, S.; Mohan, G.C.; Hatakka, A.I.; Vuorela, P.M. Miniaturization and
Validation of the Ellman’s Reaction Based Acetylcholinesterase Inhibitory Assay into 384-Well Plate Format
and Screening of a Chemical Library. Comb. Chem. High Throughput Screen. 2010, 13, 278–284. [CrossRef]
[
[PubMed]
4
4
4
4. Pohanka, M.; Jun, D.; Kuca, K. Improvement of acetylcholinesterase-based assay for organophosphates in
way of identification by reactivators. Talanta 2008, 77, 451–454. [CrossRef] [PubMed]
5. Bajgar, J. Organophosphates/nerve agent poisoning: Mechanism of action, diagnosis, prophylaxis, and
treatment. Adv. Clin. Chem. 2004, 38, 151–216. [PubMed]
6. Musílek, K.; Lipka, L.; Ra cˇ áková, V.; Ku cˇ a, K.; Jun, D.; Dohnal, V.; Doležal, M. New methods in synthesis of
acetylcholinesterase reactivators and evaluation of their potency to reactivate cyclosarin-inhibited AChE.
Chem. Pap. 2006, 60, 1–4. [CrossRef]
4
7. Ku cˇ a, K.; Cabal, J.; Jun, D.; Musílek, K. In vitro reactivation potency of acetylcholinesterase reactivators
K074 and K075 to reactivate tabun-inhibited human brain cholinesterases. Neurotox. Res. 2007, 11, 101–106.
[CrossRef] [PubMed]
4
4
5
8. Kontoyanni, M.; McClellan, L.M.; Sokol, G.S. Evaluation of Docking Performance: Comparative Data on
Docking Algorithms. J. Med. Chem. 2004, 47, 558–565. [CrossRef] [PubMed]
9. Lev, B. Multi-Criteria Decision Analysis via Ratio and Difference Judgement. Interfaces 2001, 31, 151–152.
[CrossRef]
0. Wallenius, J.; Dyer, J.S.; Fishburn, P.C.; Steuer, R.E.; Zionts, S.; Deb, K. Multiple Criteria Decision Making,
Multiattribute Utility Theory: Recent Accomplishments and What Lies Ahead. Manag. Sci. 2008, 54,
1
336–1349. [CrossRef]
5
5
5
1. Behzadian, M.; Otaghsara, S.K.; Yazdani, M.; Ignatius, J. A state-of the-art survey of TOPSIS applications.
Expert Syst. Appl. 2012, 39, 13051–13069. [CrossRef]
2. Hwang, C.; Yoon, K. Multiple Attribute Decision Making: Methods and Applications, a State of the Art Survey;
Springer: Berlin/Heidelberg, Germany, 1981.
3. Sánches-Lozano, J.M.; García-Cascales, M.S.; Lamata, M.T. Comparative TOPSIS-ELECTRE TRI methods for
optimal sites for photovoltaic solar farms. Case study in Spain. J. Clean. Prod. 2016, 127, 387–398. [CrossRef]
4. Olson, D.L. Comparison of weights in TOPSIS models. Math. Comput. Model. 2004, 40, 721–727. [CrossRef]
5. Saaty, T.L. The Analytic Hierarchy Process; MacGraw-Hill: New York, NY, USA, 1980.
6. Saaty, T.L. How to make a decision: The Analytic Hierarchy Process. Eur. J. Oper. Res. 1990, 48, 9–26.
5
5
5
[CrossRef]
5
5
5
6
7. Saaty, T.L. The Modern Science of Multicriteria Decision Making and Its Practical Applications: The
AHP/ANP Approach. Oper. Res. 2013, 61, 1101–1118. [CrossRef]
8. Dong, Q.; Saaty, T.L. An analytic hierarchy process model of group consensus. J. Syst. Sci. Syst. Eng. 2014
,
2
3, 362–374. [CrossRef]
9. Altuzarra, A.; Moreno-Jiménez, J.M.; Salvador, M. A Bayesian priorization procedure for AHP-group decision
making. Eur. J. Oper. Res. 2007, 182, 367–382. [CrossRef]
0. Ku cˇ a, K.;
Cabal, J.;
Patocka, J.;
Kassa, J. Synthesis of Bisquaternary Symmetric—
χ,δ-Bis(2-Hydroxyiminomethylpyridinium) Alkane Dibromides and Their Reactivation of
Cyclosarin-Inhibited Acetylcholinesterase. Lett. Org. Chem. 2004, 1, 84–86. [CrossRef]
1. Guex, N.; Peitsch, M.C. SWISS-MODEL and Swiss-PdbViewer: An environment for comparative protein
modeling. Electrophoresis 1997, 18, 2714–2723. [CrossRef] [PubMed]
2. Castro, A.T.; Figueroa-Villar, J.D. Molecular Structure, Conformational Analysis and Charge Distribution of
Pralidoxime: Ab Initio and DFT Studies. Int. J. Quantum Chem. 2002, 89, 135–146. [CrossRef]
3. Ku cˇ a, K.; Jun, D.; Junova, L.; Musílek, K.; Hrabinova, M.; da Silva, A.V.J.; França, T.C.C. Synthesis, Biological
Evaluation, and Docking Studies of Novel Bisquaternary Aldoxime Reactivators on Acetylcholinesterase
and Butyrylcholinesterase Inhibited by POX. Molecules 2018, 23, 1103. [CrossRef] [PubMed]
4. Deppmeier, B.J.; Driessen, A.J.; Hehre, W.J.; Johnson, J.A.; Klunzinger, P.E.; Watanabe, M.; Yu, J. PC Spartan
Pro, Version 1.0.5; Wavefunction Inc.: Irvine, CA, USA, 2000.
6
6
6
6

Molecules 2018, 23, 2954
18 of 18
6
6
6
6
5. Roche, G.B.; Freire, R.O.; Simas, A.M.; Steward, J.J. RM1: A reparameterization of AM1 for H, C, O, P, S, F, Cl,
Br, and I. J. Comput. Chem. 2006, 27, 1101–1111. [CrossRef] [PubMed]
6. Thomsen, R.; Christensen, M.H. MolDock: A New Technique for High-Accuracy Molecular Docking.
J. Med. Chem. 2006, 49, 3315–3321. [CrossRef] [PubMed]
7. Storn, R.; Price, K. Differential Evolution—A Simple and Efficient Adaptive Scheme for Global Optimization over
Continuous Spaces; Technical Report; ICSI: Berkeley, CA, USA, 1995.
8. Abraham, M.J.; Murtola, T.; Schulz, R.; Páll, S.; Smith, J.C.; Hess, B.; Lindah, E. Gromacs: High performance
molecular simulations through multi-level parallelism from laptops to supercomputers. SoftwareX 2015, 1–2,
1
9–25. [CrossRef]
9. Da Silva, A.W.S.; Vranken, W.F. ACPYPE—AnteChamber PYthon Parser Interface. BMC Res. Notes 2012, 5,
67. [CrossRef] [PubMed]
0. Humphrey, W.; Dalke, A.; Schulten, K. VMD-Visual Molecular Dynamics. J. Mol. Graph. 1996, 14, 33–38.
CrossRef]
6
7
3
[
7
7
1. Warren, D. The PyMOL Molecular Graphics System; DeLano Scientific: San Carlos, CA, USA, 2002.
2. Aczél, J.; Saaty, T.L. Procedures for synthesizing ratio judgements. J. Math. Psychol. 1983, 27, 93–102.
[CrossRef]
7
3. Alonso, J.A.; Lamata, M.T. Consistency in the Analytic Hierarchy Process: A new approach. Int. J. Uncertain.
Fuzzy Knowl. Based Syst. 2006, 14, 445–459. [CrossRef]
Sample Availability: Samples of the compounds are not available from the authors.
©
2018 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons Attribution
(CC BY) license (http://creativecommons.org/licenses/by/4.0/).